Announcement
The ECMC Network consists of world leading researchers, scientists and clinicians who drive the discovery, development and testing of new treatments to combat cancer. The interactions between the ECMC Programme Office (PO) and industry have facilitated early feasibility discussions with Key Opinion Leaders (KOLs) and enabled commercial sponsors to identify clinical trial sites to develop the breakthrough cancer drugs of the future.
The Experimental Cancer Medicine Centre (ECMC) Network, in partnership with the Health Research Authority (HRA), has been driving a key project to accelerate the setup of commercially sponsored early-phase oncology trials in the UK. This initiative is a priority for the UK, highlighted in the Government’s response to Lord O'Shaughnessy's review of commercial clinical trials and is part of the UK Recovery Resilience and Growth (RRG) programme.
As part of the year-long offering for the 2024 JING Cohort, the ECMC Programme Office organised a career pathway webinar in July. The webinar was chaired by Uma Mukherjee, UCL ECMC and we heard from Emma Kerr, Belfast ECMC and Adam Sharp, ICR ECMC.
Interested in joining the ECMC Research Nurse steering committee? Find out how here.
The ECMC Programme Office has a call open for new members for the ECMC Junior Investigator Network Group (JING) Steering Committee. Find out more
January saw the exciting kick off of the ECMC’s expanded Junior Investigator’s Training Program with our annual training event in Manchester. The network was pleased to welcome 55 Junior Investigators into our 2024 cohort, and we were joined by many of our ECMC leads and faculty as well as wonderful patient representatives who gave their time to share their stories and provide valuable insight into their clinical trial experience.
We are looking to appoint an ECMC Network Lead to lead the network and act as a key figurehead. Find out more.
The recent ECMC Haematology Network Group meeting had a focus on Teenager and Young Adults (TYA). Read a report from the meeting.